Brief intro:
- Author: Jingyi Wang, Jianbang Lin, Yefei Chen, Jing Liu, Qiongping Zheng, Mao Deng, Ruiqi Wang, Yujing Zhang, Shijing Feng, Zhenyan Xu, Weiyi Ye, Yu Hu, Jiamei Duan, Yunping Lin, Ji Dai, Yu Chen, Yuantao Li, Tao Luo, Qian Chen, Zhonghua Lu
- Journal: Cell Reports
- Doi: https://www.doi.org/10.1016/j.celrep.2023.113348
- Publication Date: 2023 Nov 28
Products/Services used in the paper
Quotation shows PackGene:All the viruses used in experiments were packaged by PackGene Biotech
Research Field:CNS
Abstract
Promoters are essential tools for basic and translational neuroscience research. An ideal promoter should possess the shortest possible DNA sequence with cell-type selectivity. However, whether ultra-compact promoters can offer neuron-specific expression is unclear. Here, we report the development of an extremely short promoter that enables selective gene expression in neurons, but not glial cells, in the brain. The promoter sequence originates from the human CALM1 gene and is only 120 bp in size. The CALM1 promoter (pCALM1) embedded in an adeno-associated virus (AAV) genome directed broad reporter expression in excitatory and inhibitory neurons in mouse and monkey brains. Moreover, pCALM1, when inserted into an all-in-one AAV vector expressing SpCas9 and sgRNA, drives constitutive and conditional in vivo gene editing in neurons and elicits functional alterations. These data demonstrate the ability of pCALM1 to conduct restricted neuronal gene expression, illustrating the feasibility of ultra-miniature promoters for targeting brain-cell subtypes.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
